OC-0059: A radiation dose-response relationship for risk of heart failure in survivors of Hodgkin lymphoma  by Aleman, B.M.P. et al.
ESTRO 35 2016                                                                                                                                                    S25 
______________________________________________________________________________________________________ 
Results: ECGs at baseline and 6 mo were available for 54 
patients, and at baseline and 12 mo for 49 patients. At 6 mo 
and 12 mo, 10 and 6 patients had ischemic changes and 12 
and 15 patients had conduction abnormalities (AF or sinus 
tachycardia). Median PTV was 403.4cm3 (Range 138.7-
1262.1). Larger PTV and ‘any ECG rhythm change’ at 6 mo 
were associated with worse OS (HR = 1.005, 95% CI: 1 - 1.01 p 
0.04; HR = 7.9843, 95% CI: 1.293 - 47.583 p 0.03 respectively) 
on MVA. Increasing values of Heart PC2, Heart PC3 and Heart 
PC7 (characterizing heart volume (vol) receiving 10-30Gy plus 
70-80Gy, 65-75Gy and 1-5Gy respectively) were associated 
with worse OS (HR = 0.844, 95% CI: 0.715– 0.995 p 0.04; HR = 
1.238, 95% CI: 1.051 - 1.457 p 0.01; HR = 1.725, 95% CI: 1.006 
- 2.958, p 0.05 respectively) on MVA. Increasing values of LA 
PC4 (LA vol receiving 65-75Gy) was associated with worse OS 
on MVA (HR = 1.129, 95% CI: 1.033 - 1.235 p <0.01). 
 
 
Conclusion: We found evidence of a possible association 
between lower OS in IDEAL-CRT patients and high PTV, 
ischaemic or conduction change on ECG at 6 mo, and 
relatively high heart volume receiving doses <5Gy, 10-30Gy, 
65-75Gy and 70-80Gy with the 65-75Gy localising to LA. 
Further prospective studies are required to improve 
understanding of cardiac irradiation in NSCLC. 
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Purpose or Objective: Breast cancer patients with 
cardiovascular risk factors are at increased risk of radiation- 
and chemotherapy- induced cardiovascular complications. 
Presence of coronary artery calcifications (CAC) is a major 
independent risk factor for cardiovascular disease (CVD). This 
study investigates the prevalence of CAC in breast cancer 
patients on radiotherapy (RT) planning CT scans, and its 
association with cardiovascular risk factors. 
 
Material and Methods: This study was conducted within the 
Utrecht cohort for Multiple BReast cancer intErvention 
studies and Long-term evaLuAtion (UMBRELLA), and includes 
561 breast cancer patients undergoing planning CT scans at 
the UMC Utrecht between October 2013-March 2015. CAC was 
automatically scored using a validated algorithm that 
identifies CAC with a supervised pattern and threshold of 130 
Hounsfield Units. Patients were categorized according to CAC 
(Agatston) scores: 0, 1-10, 11-100, 101-400, >400.  
Cardiovascular risk factors (diabetes, smoking status, 
hypercholesterolemia, hypertension, history of CVD) were 
collected for 36 patients with intermediate to high CVD risk 
(scores>100), and for a random selection of patients with fair 
to moderate CVD risk (1≤ scores ≤100, n=36) and low CVD risk 
(without CAC, i.e. scores of 0, n=36). Demographic, disease 
characteristics, and presence of cardiovascular risk factors 
were compared between groups using Chi-square analysis and 
Kruskal-Wallis test for categorical and continuous data 
respectively. 
 
Results: Median age of the cohort was 58 years (range: 26-
85). There were 427 (76%) patients without CAC, 50 (9%) with 
scores between 1-10, 43 (7%) with scores between 11-100, 
and 36 (7%) patients with scores >100. Patients with scores 
>100 had significantly more often diabetes than those 
without CAC (28% vs. 3%, p<0.001). Patients with scores >100 
had more often three to four CVD risk factors compared to 
patients with scores between 1-100 or without CAC: 30%, 5%, 
0% respectively, p=0.002. Ten (28%) patients with scores >100 
did not have any other CVD risk factor  
 
Conclusion: CAC is present in one in four breast cancer 
patients. In one third of patients with CAC scores >100, no 
other CVD risk factors were present, and these patients 
would not have been identified as high risk using standard 
CVD risk factors. Since CAC can be automatically detected 
without additional cost or radiation exposure in breast cancer 
patients undergoing RT, it represents a simple and useful way 
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Purpose or Objective: Cardiovascular diseases are 
increasingly recognized as late effects of Hodgkin lymphoma 
(HL) treatment. Radiation therapy is known to contribute to 
the risk of heart failure (HF), but a dose-response 
relationship has yet not been well described. The purpose of 
this study was to identify risk factors for HF, and to quantify 
effects of radiation dose to the heart, chemotherapy, and 
other cardiovascular risk factors. 
 
Material and Methods: We conducted a nested case-control 
study in a cohort of 2,617 5-year HL survivors, treated 
between 1965-1995. Cases were patients who developed HF 
in the form of either symptomatic congestive heart failure or 
cardiomyopathy (Common Terminology Criteria for Adverse 
Events version 4.0: grade ≥2) as their first clinically 
significant heart disease. Detailed treatment information was 
collected from medical records of 91 cases and 278 matched 
controls. Mean heart dose (MHD) was retrospectively 
estimated by reconstruction of individual treatments on 
representative computed tomography datasets. All statistical 
tests were two-sided. 
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Results: The median interval between HL and HF was 20.6 
years. Fifty-seven percent of the cases had died at the end of 
follow-up, with a median time from HF to death of 3.6 years 
(interquartile range: 0.2-5.6 years). Mediastinal radiotherapy 
was applied through parallel-opposed fields. Average MHD for 
cases treated with RT was 25 Gy and for controls 22 Gy. Risk 
of HF increased in a non-linear way, with no increase at a 
MHD of 10 Gy, a 1.2-fold increased risk at a MHD of 20 Gy, 
and a 2.5-fold increased risk at a MHD of 30 Gy. Relatively 
low doses of anthracyclines (10-279 mg/m2) were associated 
with a 3.2-fold increased risk of developing HF (95%CI: 1.3-
7.7) compared with patients who did not receive 
anthracyclines. High doses of anthracyclines (280-800 
mg/m2) were associated with a similarly increased risk (RR: 
2.8, 95%CI: 1.6-5.1). For patients who received 
anthracyclines in combination with mediastinal radiotherapy 
the risk of HF (RR: 2.90 at a MHD of 25 Gy) was slightly higher 
than the risk of mediastinal radiotherapy without 
anthracyclines (RR: 1.8 at a MHD of 25 Gy), although the 
difference was not statistically significant (p 
interaction=0.10). Classical risk factors for cardiovascular 
diseases did not confound or modify the association between 
treatment-related risk factors and HF risk. 
 
Conclusion: Risk of HF increased non-linearly with mean 
heart dose in patients treated for HL. Our findings can be 
used to predict HF risk and may therefore be useful for 
patients and doctors both before treatment, during radiation 
treatment planning and in follow-up. Patients who received 
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Purpose or Objective: Among 6039 patients with Hodgkin 
lymphoma enrolled in nine successive EORTC-GELA 
randomized trials (1964-2004), the effect of individual 
radiotherapy and chemotherapy doses on the risk of 
developing cardiac disease was investigated. We specifically 
analysed the added value from radiation dose-volume metrics 
on cardiac risk prediction as well as the impact of relapse 
treatment. 
 
Material and Methods: For all patients, dose-volume metrics 
for the heart (mean dose, volume receiving ≥5 Gy (V5Gy), 
V10Gy, V20Gy, V30Gy, V40Gy) were retrospectively 
estimated by reconstructing individual treatments on 
representative computed tomography datasets. Cumulative 
doses of anthracyclines and vinca-alkaloids (mg/m2) were 
also obtained individually. Relapse occurring before a cardiac 
disease was analysed qualitatively (no, yes). Cardiac disease 
was reported during follow-up and through a patient-
reported questionnaire (LSQ responders, 2009-2010 cross-
sectional study). A multivariable Cox proportional hazards 
model with backwards selection was applied to test for 
patient- and treatment-related factors associated with 
cardiac disease. The resulting model was compared to a 
"mean heart dose"-model in terms of prognostic 
discrimination ability. 
 
Results: 599 patients developed at least one cardiac disease 
event (465 events obtained from the 1919 LSQ responders). 
Significant predictors of cardiac disease were: cumulative 
dose of anthracyclines (HR=1.002 per 1 mg/m2 increase in 
cumulative dose; 95% CI, 1.001-1.003, p=0.005); (any) 
treatment given for a relapse (HR=1.286; 95% CI,1.001-1.65, 
p=0.049) and the radiation dose-volume metrics V30Gy 
(HR=1.007 per 1% increase in dose; 95% CI, 1.003-1.011, 
p=0.001) and V40Gy (HR=1.018 per 1% increase in dose; 95% 
CI,1.008-1.029, p<0.001). The freedom from cardiac disease 
estimates with the "V30Gy, V40Gy"-model are plotted against 
a "mean heart dose"-model (= mean heart dose, cumulative 
dose of anthracyclines, any relapse treatment) in figure 1. 
 
 
Figure 1: Freedom from cardiac disease estimates with the 
resulting “V30Gy, V40Gy”-model versus a “mean heart dose”-
model. 
 
Conclusion: In patients treated for Hodgkin lymphoma, the 
radiation dose-volume metrics V30Gy and V40 Gy, the 
cumulative dose of anthracyclines, and (any) treatment given 
for a relapse have a significant impact on the risk of 
subsequent cardiac disease. There seems to be no improved 
discrimination ability of the prognostic model when using 
radiation dose-volume metrics compared to the mean heart 
dose metric. 
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Purpose or Objective: A novel approach to treatment 
planning for focal brachytherapy is described, utilizing a 
biologically-based inverse optimization algorithm and 
